| abstract |
Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes). |